Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials
Alzheimer's & Dementia · 2023-02 · 19 (2) · 696-707
DOI: 10.1002/alz.12737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, online erschienen am 10.08.2022. Verfasst von Jessica B Langbaum und 23 weiteren Autor:innen. Beteiligte Einrichtung: Banner Alzheimer's Institute, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, FDA HHS.
Themen: Demenz
Abstract (Originalsprache)
Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and retention of a large number of qualified, diverse volunteers to participate in clinical research studies remain among the key barriers to the successful completion of AD clinical trials. An advisory panel of experts from academia, patient‐advocacy organizations, philanthropy, non‐profit, government, and industry convened in 2020 to assess the critical challenges facing recruitment in Alzheimer's clinical trials and develop a set of recommendations to overcome them. This paper briefly reviews existing challenges in AD clinical research and discusses the feasibility and implications of the panel's recommendations for actionable and inclusive solutions to accelerate the development of novel therapies for AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Banner Alzheimer's Institute, Phoenix, Arizona, USA.
- Sol Price School of Public Policy and Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California, USA.
- Departments of Anatomy & Neurobiology, Neurology and Epidemiology, Boston University Schools of Medicine and Public Health, Boston, Massachusetts, USA.
- Gates Ventures, Kirkland, Washington, USA.
- Cogstate Ltd, Reading, UK.
- Clara Health, San Francisco, California, USA.
Förderung
- NIA NIH HHS
- FDA HHS
Zitieren
APA
Langbaum, J. B., Zissimopoulos, J., Au, R., Bose, N., Edgar, C. J., Ehrenberg, E., Fillit, H., Hill, C. V., Hughes, L., Irizarry, M., Kremen, S., Lakdawalla, D., Lynn, N., Malzbender, K., Maruyama, T., Massett, H. A., Patel, D., Peneva, D., Reiman, E. M., …, & Aisen, P. S. (2023). Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. Alzheimer's & Dementia, 19(2), 696-707. https://doi.org/10.1002/alz.12737
Vancouver
Langbaum JB, Zissimopoulos J, Au R, Bose N, Edgar CJ, Ehrenberg E, et al. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. Alzheimer's & Dementia. 2023;19(2):696-707. doi:10.1002/alz.12737
BibTeX
@article{Langbaum2023,
author = {Langbaum, Jessica B and Zissimopoulos, Julie and Au, Rhoda and Bose, Niranjan and Edgar, Chris J and Ehrenberg, Evan and Fillit, Howard and Hill, Carl V and Hughes, Lynne and Irizarry, Michael and Kremen, Sarah and Lakdawalla, Darius and Lynn, Nancy and Malzbender, Kristina and Maruyama, Tetsuyuki and Massett, Holly A and Patel, Deep and Peneva, Desi and Reiman, Eric M and Romero, Klaus and Routledge, Carol and Weiner, Michael W and Weninger, Stacie and Aisen, Paul S},
title = {Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {2},
pages = {696--707},
doi = {10.1002/alz.12737}
}
EUVIMED